[{"orgOrder":0,"company":"Church & Dwight Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Dentifrice","moa":"Bacterial biofilm","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Church & Dwight Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Church & Dwight Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Church & Dwight Co \/ Undisclosed"},{"orgOrder":0,"company":"Church & Dwight Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Dentifrice","moa":"Bacterial biofilm","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Church & Dwight Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Church & Dwight Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Church & Dwight Co \/ Undisclosed"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Vantage Data Designs | Syneos Health | Agility Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Gel","sponsorNew":"Armata Pharmaceuticals \/ Vantage Data Designs | Syneos Health | Agility Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Vantage Data Designs | Syneos Health | Agility Clinical"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Vantage Data Designs | E Squared Trials and Registries | Agility Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Strip","sponsorNew":"Armata Pharmaceuticals \/ Vantage Data Designs | E Squared Trials and Registries | Agility Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Vantage Data Designs | E Squared Trials and Registries | Agility Clinical"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armata Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armata Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armata Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armata Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armata Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dexcel Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Dexcel Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexcel Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dexcel Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Universitat Internacional de Catalunya","sponsor":"Dentaid","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Universitat Internacional de Catalunya","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitat Internacional de Catalunya \/ Dentaid","highestDevelopmentStatusID":"8","companyTruncated":"Universitat Internacional de Catalunya \/ Dentaid"},{"orgOrder":0,"company":"Contipro Pharma a.s","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Contipro Pharma a.s","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Contipro Pharma a.s \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Contipro Pharma a.s \/ Undisclosed"},{"orgOrder":0,"company":"Iroko Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Naproxen","moa":"Cyclooxygenase","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Iroko Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iroko Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Iroko Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PerioC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"PerioC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Gel","sponsorNew":"PerioC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PerioC \/ Undisclosed"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Fluoride","moa":"Enamel","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"Geistlich Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SWITZERLAND","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Taurolidine","moa":"Cell wall","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Geistlich Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geistlich Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Geistlich Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Geistlich Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SWITZERLAND","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Taurolidine","moa":"Cell wall","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Geistlich Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geistlich Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Geistlich Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Universidad de los Andes, Chile","sponsor":"Corporaci\u00f3n de Fomento de la Producci\u00f3n, Chile","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CHILE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Universidad de los Andes, Chile","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad de los Andes, Chile \/ Corporaci\u00f3n de Fomento de la Producci\u00f3n, Chile","highestDevelopmentStatusID":"8","companyTruncated":"Universidad de los Andes, Chile \/ Corporaci\u00f3n de Fomento de la Producci\u00f3n, Chile"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sodium Fluoride","moa":"Hydroxyapatite","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"PROCTER AND GAMBLE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sodium Fluoride","moa":"Hydroxyapatite","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"PROCTER AND GAMBLE","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PROCTER AND GAMBLE \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PROCTER AND GAMBLE \/ Undisclosed"},{"orgOrder":0,"company":"University of Padova, School of Dental Medicine","sponsor":"Geistlich Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Deproteinized Bovine Bone","moa":"Hydroxylapatite","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"University of Padova, School of Dental Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Padova, School of Dental Medicine \/ Geistlich Pharma","highestDevelopmentStatusID":"8","companyTruncated":"University of Padova, School of Dental Medicine \/ Geistlich Pharma"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"Integra Medical Inc. | University of Toronto | University of Western Ontario, Canada | Ontario Centres of Excellence","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CANADA","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ Integra Medical Inc. | University of Toronto | University of Western Ontario, Canada | Ontario Centres of Excellence","highestDevelopmentStatusID":"8","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ Integra Medical Inc. | University of Toronto | University of Western Ontario, Canada | Ontario Centres of Excellence"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"University of Washington","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Silver Diamine Fluoride","moa":"Immune","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ University of Washington"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"University of California, San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Silver Diamine Fluoride","moa":"Immune","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ University of California, San Francisco","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ University of California, San Francisco"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"University of Washington","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Silver Diamine Fluoride","moa":"Immune","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ University of Washington"},{"orgOrder":0,"company":"Concordia Dent Srl","sponsor":"Carol Davila University of Medicine and Pharmacy | Romanian National Authority for Scientific Research and Innovation | University Politechnica of Bucharest | TURKEY MEDISEN Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Concordia Dent Srl","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Concordia Dent Srl \/ Carol Davila University of Medicine and Pharmacy | Romanian National Authority for Scientific Research and Innovation | University Politechnica of Bucharest | TURKEY MEDISEN Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Concordia Dent Srl \/ Carol Davila University of Medicine and Pharmacy | Romanian National Authority for Scientific Research and Innovation | University Politechnica of Bucharest | TURKEY MEDISEN Ltd"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Pharma Power Biotec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"TAIWAN","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"Radion-Pdt","moa":"Photosensitiser","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Pharma Power Biotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharma Power Biotec \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharma Power Biotec \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Indiana University","sponsor":"Water Pik, Inc. | Delta Dental Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Powder","sponsorNew":"Indiana University \/ Water Pik, Inc. | Delta Dental Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Indiana University \/ Water Pik, Inc. | Delta Dental Foundation"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"APD515","moa":"Salivary secretion","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"PF-05089771","moa":"Sodium channel protein type IX alpha subunit","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"PF-04531083","moa":"Sodium channel protein type X alpha subunit","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AAV2-hAQP1","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MeiraGTx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MeiraGTx \/ Undisclosed"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AAV2-hAQP1","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MeiraGTx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MeiraGTx \/ Undisclosed"},{"orgOrder":0,"company":"AngioLab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ALH-L1005","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"AngioLab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AngioLab \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AngioLab \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Calcium Sodium Phosphosilicate","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"BioSci Research","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Calcium Sodium Phosphosilicate","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ BioSci Research","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ BioSci Research"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Calcium Sodium Phosphosilicate","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Colgate Maximum Cavity Protection Plus Sugar Acid Neutralizer","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"Biomedical Development","sponsor":"National Heart, Lung, and Blood Institute | University of Texas System","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Iocide","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Biomedical Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomedical Development \/ National Heart, Lung, and Blood Institute | University of Texas System","highestDevelopmentStatusID":"8","companyTruncated":"Biomedical Development \/ National Heart, Lung, and Blood Institute | University of Texas System"},{"orgOrder":0,"company":"Biomedical Development","sponsor":"National Heart, Lung, and Blood Institute | University of Kentucky","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Iocide","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Biomedical Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomedical Development \/ National Heart, Lung, and Blood Institute | University of Kentucky","highestDevelopmentStatusID":"8","companyTruncated":"Biomedical Development \/ National Heart, Lung, and Blood Institute | University of Kentucky"},{"orgOrder":0,"company":"HysensBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KH001","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"HysensBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HysensBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HysensBio \/ Undisclosed"},{"orgOrder":0,"company":"HysensBio","sponsor":"The Forsyth Institute","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KH001","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"HysensBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HysensBio \/ The Forsyth Institute","highestDevelopmentStatusID":"8","companyTruncated":"HysensBio \/ The Forsyth Institute"},{"orgOrder":0,"company":"HysensBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"KH001","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"HysensBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HysensBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HysensBio \/ Undisclosed"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Meridol","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"Sangi","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nano-HAP","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"University of Texas Health Science Center at San Antonio \/ Sangi","highestDevelopmentStatusID":"8","companyTruncated":"University of Texas Health Science Center at San Antonio \/ Sangi"},{"orgOrder":0,"company":"NanoSHIFT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NTC-510","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"NanoSHIFT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NanoSHIFT \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NanoSHIFT \/ Undisclosed"},{"orgOrder":0,"company":"SCHULKE & MAYR G.M.B.H.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Octenidine Hydrochloride","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"SCHULKE & MAYR G.M.B.H.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCHULKE & MAYR G.M.B.H. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SCHULKE & MAYR G.M.B.H. \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Oxalic Acid","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Advantage Dental Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Dental Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Dental Services \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Dental Services \/ Undisclosed"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"University of Washington","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ University of Washington"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ Undisclosed"},{"orgOrder":0,"company":"Arcadia Consumer Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Chlorite","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Arcadia Consumer Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcadia Consumer Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcadia Consumer Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"YH14642","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"YH23537","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"McNeil Consumer Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"McNeil Consumer Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Tablet","sponsorNew":"McNeil Consumer Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"McNeil Consumer Health \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Johnson & Johnson"},{"orgOrder":0,"company":"Nevakar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nevakar \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nevakar \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Potassium Nitrate","moa":"Voltage-gated inwardly rectifying potassium channel KCNH2","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Potassium Nitrate","moa":"Voltage-gated inwardly rectifying potassium channel KCNH2","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Potassium Nitrate","moa":"Voltage-gated inwardly rectifying potassium channel KCNH2","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Potassium Nitrate","moa":"Voltage-gated inwardly rectifying potassium channel KCNH2","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Strip","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Government Dental College and Research Institute, Bangalore","sponsor":"Himalaya Drug Company Ltd. India","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Government Dental College and Research Institute, Bangalore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Government Dental College and Research Institute, Bangalore \/ Himalaya Drug Company Ltd. India","highestDevelopmentStatusID":"8","companyTruncated":"Government Dental College and Research Institute, Bangalore \/ Himalaya Drug Company Ltd. India"},{"orgOrder":0,"company":"Dubai Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.A.E","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Dubai Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Dubai Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dubai Health \/ Undisclosed"},{"orgOrder":0,"company":"HysensBio","sponsor":"Byoung-Moo Seo","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KH001","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"HysensBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HysensBio \/ Byoung-Moo Seo","highestDevelopmentStatusID":"8","companyTruncated":"HysensBio \/ Byoung-Moo Seo"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Dubai Health

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Dubai Health

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Hydroxyapatite is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Molar Incisor Hypomineralisation.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 16, 2025

                          Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Sodium fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gingivitis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 25, 2025

                          Lead Product(s) : Sodium Fluoride

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          HysensBio

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          HysensBio

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : KH001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dental Caries.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 30, 2024

                          Lead Product(s) : KH001

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase II

                          Sponsor : Byoung-Moo Seo

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in phase II clinical studies for the treatment of Dental Plaque.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 22, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Meridol is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gingivitis.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          August 21, 2024

                          Lead Product(s) : Meridol

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : AAV2-hAQP1 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Xerostomia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 09, 2024

                          Lead Product(s) : AAV2-hAQP1

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          HysensBio

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          HysensBio

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : KH001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dentin Sensitivity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 18, 2024

                          Lead Product(s) : KH001

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase II

                          Sponsor : The Forsyth Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          HysensBio

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          HysensBio

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : KH001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dentin Sensitivity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 20, 2024

                          Lead Product(s) : KH001

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : AAV2-hAQP1 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Xerostomia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 03, 2023

                          Lead Product(s) : AAV2-hAQP1

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Advantage Silver Dental Arrest

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Advantage Silver Dental Arrest

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Silver Diamine Fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dental Caries.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 04, 2023

                          Lead Product(s) : Silver Diamine Fluoride

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase II

                          Sponsor : University of Washington

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank